1. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines. Appendix A. 2021 Jan 12 [cited 2021 Jan 13]. Available from:
2. Puranik A, Lenehan PJ, Silvert E, Neisen MJM Corchado-Garcia J, O'Horo JC et al. Comparison of two highly effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv. 2021 Aug 9. doi: 10.1101/2021.08.06.21261707:2021.08.06.21261707.
3. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRXiv. 2021 Jul 16. doi: 10.1101/2021.06.28.21259420.
4. Tang P, Hasan MR, Chematelly H, Yassine HM, Benslimane FM, Khatib HAA, et al. BNT1162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. medRxiv. 2021 Aug 11. doi: 10.1101/2021.08.11.21261885.
5. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mort Wkly Rep. 2021;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
6. Children's Hospital of Philadelphia [Internet]. Philadelphia: Children's Hospital of Philadelphia; c2021. Questions and answers about COVID-19 vaccines. 2020 Dec 31 [cited 2021 Jan 8]. Available from:
7. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines. 2021 April 23 [cited 2021 April 28]. Available from:
8. U.S. Food & Drug Administration [Internet]. Silver Spring (MD): U.S. Food & Drug Administration. 2020 meeting materials, vaccines and related biological products advisory committee December 10, 2020 meeting announcement. 2020 Dec 10 [cited 2021 Jan 5]. Available from:
9. U.S. Food & Drug Administration [Internet]. Silver Spring (MD): U.S. Food & Drug Administration. 2020 meeting materials, vaccines and related biological products advisory committee December 17, 2020 meeting announcement. 2020 Dec 17 [cited 2021 Jan 5]. Available from:
10. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines. Appendix B. 2021 Jan 12 [cited 2021 Jan 13]. Available from:
11. Pfizer Canada ULC. Pfizer-BioNTech COVID-19 Vaccine Product Monograph [Internet]. 2020 Dec 9 [cited 2021 February 19]. 26 p. Available from:
12. Moderna Therapeutics Inc. Moderna COVID-19 Vaccine Product Monograph [Internet]. 2020 Dec 23 [cited 2021 Jan 5]. 19 p. Available from:
13. Pfizer-BioNTech COVID-19 Vaccine [Internet}. Kirkland (QC): Pfizer Canada ULC; c2021. Dosing and administration; 2020 Dec [cited 2020 Dec 22]. Available from:
14. Moderna. mRNA-1273 Sponsor Briefing Document [Internet]. Silver Spring (MD): FDA, Vaccines and Related Biological Products Advisory Committee; 2020 Dec 17 [cited 2021 February 22]. 83p. Available from:
15. Blumenthal KG, Freeman EE, Saff RR, et al. Delayed Large Local Reactions to mRNA1273 Vaccine against SARS-CoV-2. N Engl J Med. Published online March 3, 2021:NEJMc2102131. doi:10.1056/NEJMc2102131
16. Canadian Society of Allergy and Clinical Immunology [Internet]. Orleans (ON): Canadian Society of Allergy and Clinical Immunology. SARS-CoV-2 vaccine testing & administration guidance for allergists/immunologists from CSACI. 2021 April 10 [cited 2021 April 29]. Available from:
17. Government of the United Kingdom. Medicines & Healthcare Products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. [Internet]; 2021 [cited 2021 Aug 30]. Available from:
18. Public Health Ontario. Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario. [Internet]; 2021 [cited 2021 Aug 30]. Available from:
19. Public Health Agency of Canada. Canadian COVID-19 vaccination safety report. [Internet]; 2021 [cited 2021 Aug 30]. Available from:
20. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. [Internet]; 2021 [cited 2021 Aug 30]. Available from:
21. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet [Internet]. 2021 Jan 9 [cited 2021 Mar 16];397(10269):99-111. Available from:
22. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet [Internet]. 2021 Mar 6 [cited 2021 Mar 16];397(10277):881-891. Available from:
23. Public Heath Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines. 2021 May 3 [cited 2021 May 14]. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html
24. European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. April 7, 2021.
25. Health Canada. Recalls and Safety Alerts. Health Canada provides update on the AstraZeneca and COVISHIELD COVID-19 vaccines. Updated April 16, 2021. Accessed April 28, 2021. https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75389a-eng.php#:~:text=Healthcare%20professionals%20should%20tell%20people,headaches%20or%20blurred%20vision%3B%20or
26. Centers for Disease Control and Prevention. Atlanta GA. The Advisory Committee on Immunization Practices’ (ACIP) updated recommendations on the use of the Janssen (Johnson & Johnson) COVID-19 vaccine. Accessed April 24, 2021. Available from:
27. Pai M, Grill A, Ivers N, et al. Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) Following AstraZeneca COVID-19 Vaccination. March 26, 2021.
28. Moayyedi P, Fernandes A, Yuan C, Farbod Y, Pittayanon R, Kanno T. The effects of vaccination in immunocompromised people. Rapid review of research studies on immunogenicity, safety, and efficacy/effectiveness of COVID-19 vaccines in immunocompromised individuals (unpublished draft). Toronto (ON): SPOR Evidence Alliance; 2021 Aug 25
29. Barda N, Dagan N, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a nationwide mass vaccination setting. Reply. N Engl J Med. 2021 May 20;384(20):1970. doi: 10.1056/NEJMc2104281.
30. Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2021 May 17:ciab438. doi: 10.1093/cid/ciab438.
31. Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Pillai PS, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. Preprint posted on khub. 2021 Jul 9.
32. National Advisory Committee on Immunization. Canadian Immunization Guide [Internet]. Evergreen ed. Ottawa (ON): Public Health Agency of Canada; 2012 [updated 2020 Dec 24]. Part 3 - Immunization in pregnancy and breastfeeding; [cited 2021 Jan10]. Available from:
33. The Society of Obstetricians and Gynaecologists of Canada [Internet]. Ottawa (ON): The Society of Obstetricians and Gynaecologists of Canada. SOGC statement on COVID-19 vaccination in pregnancy. 2021 Jan 11 [cited 2021 Jan 13]. Available from:
34. Castillo E and Poliquin V. Immunization in pregnancy. J Obstet Gynaecol Can [Internet]. 2018 Apr [cited 2021 Jan 10];40(4):478-89. Available from:
35. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, Marquez PL, Olson CK, Liu R, Chang KT, Ellington SR, Burkel VK, Smoots AN, Green CJ, Licata C, Zhang BC, Alimchandani M, Mba-Jonas A, Martin SW, Gee JM, Meaney-Delman DM; CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2104983. Epub ahead of print. PMID: 33882218.
36. Canadian Rheumatology Association. Recommendations on COVID-19 vaccination in persons with autoimmune rheumatic disease. January 2021.
37. Centers for Disease Control and Prevention [Internet]. Atlanta (GA): U.S. Department of Health & Human Services. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States; [updated 2021 Jan 6; cited 2021 Jan 8]. Available from:
38. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. 2021 Mar 8 [cited 2021 Mar 16]. Available from:
39. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother [internet]. 2016 Sep 1 [cited 2021 Jan 10];12(9):2391-402. Available from:
40. Chau-Giendinning H, Baber B, Neher JO, Safranek S. Do prophylactic antipyretics reduce vaccination-associcated symptoms in children? J Fam Pract [Internet]. 2020 Apr [cited 2021 Jan 10];69(3):E21-22. Available from:
41. Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review. PLoS One [Internet]. 2014 Sep 2 [cited 2021 Jan 10];9(9):e106629. Available from:
42. BC Cancer. COVID-19 and Cancer Screening. Does the COVID-19 vaccine affect my screening mammogram? Accessed April 28, 2021.
43. Vander Leek TK, Chan ES, Connors L et al. COVID-19 vaccine testing & administration guidance for allergists/immunologist from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol 17, 29 (2021).
44. Public Health Agency of Canada [Internet]. Ottawa (ON): Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines. Appendix A. 2021 Jul 22 [cited 2021 Sep 23]. Available from:
45. Anaphylaxis and other Acute Reactions following Vaccination: Canadian Immunization Guide-Canada.ca [Internet]. 2020. Available from:
49. Krantz MS, Kwah JH, Stone CA Jr, Phillips EJ, Ortega G, Banerji A, et al. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. JAMA Intern Med. 2021 Jul 26. doi: 10.1001/jamainternmed.2021.3779.
50. Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA,Jr, Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose! Allergy. 2021 Sep;76(9):2916,2920. doi: 10.1111/all.14958.
51. Kessel A, Bamberger E, Nachshon L, Rosman Y, Confino-Cohen R, Elizur A. Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose. Allergy. 2021 Aug 9. doi: 10.1111/all.15038.
52. Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Ann Allergy Asthma Immunol. 2021 Jul;127(1):133,134. doi: 10.1016/j.anai.2021.03.024.